Unicentric castleman's disease located in the lower extremity: a case report

<p>Abstract</p> <p>Background</p> <p>Castleman's disease is a rare form of localized lymph node hyperplasia of uncertain etiology. Although the mediastinum is the most common site of involvement, rare cases occurring in lymph node bearing tissue of other localization have been reported, including only a few intramuscular cases. Unicentric and multicentric Castleman's disease are being distinguished, the latter harboring an unfavorable prognosis.</p> <p>Case Presentation</p> <p>Here, we present a case of unicentric Castleman's disease in a 37-year-old woman without associated neoplastic, autoimmune or infectious diseases. The lesion was located in the femoral region of the right lower extremity and surgically resected after radiographic workup and excisional biopsy examinations. The tumor comprised lymphoid tissue with numerous germinal centers with central fibrosis, onion-skinning and rich interfollicular vascularization. CD23-positive follicular dendritic cells were detected in the germinal centers and numerous CD138-positive plasma cells in interfollicular areas. The diagnosis of mixed cellularity type Castleman's disease was established and the patient recovered well.</p> <p>Conclusions</p> <p>In conclusion, the differential diagnosis of Castleman's disease should be considered when evaluating a sharply demarcated, hypervascularized lymphatic tumor located in the extremities. However, the developmental etiology of Castleman's disease remains to be further examined.</p

Nanofracturing: a new technique for bone marrow stimulation in equine cartilage repair

Microfracture is the current standard in treatment of focal full-thickness cartilage lesions in horses, but clinical outcome may vary. Nanofracture is a novel technique that uses a commercially developed device to yield smaller diameter perforations with deeper penetration into the subchondral bone. Experimentally, in rabbits and sheep, nanofracture has been shown to result in superior repair compared to microfracture. The objective was to study the feasibility and preliminary outcome of nanofracture using a commercial device for treatment of cartilage defects in horses. Nanofracture was tested ex vivo in n=2 cadaveric equine stifle joints and in vivo in n=8 horses with experimental partial thickness cartilage defects in the medial femoral trochlear ridge. These were treated with an experimental biomaterial or nanofracture, and repair tissue was studied macroscopically (ICRS-I score) and microscopically (histological ICRS-II score and micro-CT) after 7 months. Both in cadaveric equine stifle joints and in vivo, the nanofracture device could readily be applied and allowed easy penetration of the subchondral bone. Repair tissue after 7 months was graded ‘near-normal’ macroscopically, while histologically, the abundant repair tissue proved mainly fibrocartilaginous in nature. Micro-CT revealed near-full restoration of mid-lesion cartilage layer thickness but altered subchondral bone microarchitecture. The in vivo study did not include a control group treated with conventional microfracture for comparison. To our knowledge, this is the first report on bone marrow stimulation using nanofracture as a potential method to enhance chondral defect repair in horses. In the in vivo study, no clinical adverse effects were observed, and promising good defect filling with fibrocartilaginous tissue was seen 7 months after treatment.La microfractura es el estándar actual en el tratamiento de lesiones focales de cartílago de grosor completo en caballos, pero el resultado clínico puede variar. La nanofractura es una técnica novedosa que utiliza un dispositivo desarrollado comercialmente para producir perforaciones de menor diámetro con una penetración más profunda en el hueso subcondral. Experimentalmente, en conejos y ovejas, se ha demostrado que la nanofractura da lugar a una reparación superior en comparación con la microfractura. El objetivo era estudiar la viabilidad y el resultado preliminar de la nanofractura utilizando un dispositivo comercial para el tratamiento de defectos del cartílago en caballos. La nanofractura se probó ex vivo en n=2 articulaciones de la ahogada cadavérica equina e in vivo en n=8 caballos con defectos de cartílago de espesor parcial experimental en la cresta troclear del fémur medial. Estos fueron tratados con un biomaterial experimental o nanofractura, y el tejido de reparación fue estudiado macroscópicamente (puntuación ICRS-I) y microscópicamente (puntuación histológica ICRS-II y micro-TC) después de 7 meses. Tanto en las articulaciones de la ahogada equina cadavérica como in vivo, el dispositivo de nanofractura podía aplicarse fácilmente y permitía una fácil penetración del hueso ubcondral. El tejido de reparación después de 7 meses fue calificado acroscópicamente como 'casi normal', mientras que histológicamente, el abundante tejido de reparación demostró ser principalmente de naturaleza fibrocartilaginosa. La micro-TC reveló una restauración casi completa del grosor de la capa de cartílago de la lesión media, pero alteró la microarquitectura del hueso subcondral. El estudio in vivo no incluyó un grupo de control tratado con microfractura convencional para la comparación. Hasta donde sabemos, este es el primer informe sobre la estimulación de la médula ósea usando la nanofractura como un método potencial para mejorar la reparación de defectos condrales en caballos. En el estudio in vivo, no se observaron efectos clínicos adversos, y se vio un buen relleno del defecto con tejido fibrocartilaginoso 7 meses después del tratamiento.Escuela de Medicina Veterinari

Long-term in vivo performance of low-temperature 3D-printed bioceramics in an equine model

Bone has great self-healing capacity, but above a certain critical size, bone defects will not heal spontaneously, requiring intervention to achieve full healing. Among the synthetic calcium phosphate (CaP) bone replacement materials, brushite (CaHPO4·2H2O)-based materials are of particular interest because of their degree of solubility and the related high potential to promote bone regeneration after dissolution. They can be produced tailor-made using modern three-dimensional (3D) printing technology. Although this type of implant has been widely tested in vitro, there are only limited in vivo data and less so in a relevant large animal model. In this study, material properties of a 3D-printed brushite-based scaffold are characterized, after which the material is tested by in vivo orthotopic implantation in the equine tuber coxae for 6 months. The implantation procedure was easy to perform and was well tolerated by the animals, which showed no detectable signs of discomfort. In vitro tests showed that compressive strength along the vertical axis of densely printed material was around 13 MPa, which was reduced to approximately 8 MPa in the cylindrical porous implant. In vivo, approximately 40% of the visible volume of the implants was degraded after 6 months and replaced by bone, showing the capacity to stimulate new bone formation. Histologically, ample bone ingrowth was observed. In contrast, empty defects were filled with fibrous tissue only, confirming the material’s osteoconductive capacity. It is concluded that this study provides proof that the 3D-printed brushite implants were able to promote new bone growth after 6 months’ implantation in a large animal model and that the new equine tuber coxae bone model that was used is a promising tool for bone regeneration studies.El hueso tiene una gran capacidad de autocuración, pero por encima de un cierto tamaño crítico, los defectos óseos no se curan espontáneamente, por lo que es necesario intervenir para lograr una curación completa. Entre los materiales sintéticos de sustitución ósea de fosfato de calcio (CaP), los materiales a base de brusquitos (CaHPO4-2H2O) son de particular interés por su grado de solubilidad y el elevado potencial que presentan para promover la regeneración ósea después de la disolución. Pueden producirse a medida utilizando la moderna tecnología de impresión tridimensional (3D). Aunque este tipo de implante ha sido ampliamente probado in vitro, sólo hay datos limitados in vivo y menos en un modelo relevante de animal grande. En este estudio se caracterizan las propiedades del material de un andamiaje tridimensional impreso a base de grafito, tras lo cual el material se prueba mediante la implantación ortotópica in vivo en el tubérculo equino coxae durante 6 meses. El procedimiento de implantación fue fácil de realizar y fue bien tolerado por los animales, que no mostraron ningún signo detectable de molestia. Las pruebas in vitro demostraron que la resistencia a la compresión a lo largo del eje vertical del material densamente impreso era de alrededor de 13 MPa, que se redujo a aproximadamente 8 MPa en el implante cilíndrico poroso. En vivo, aproximadamente el 40% del volumen visible de los implantes se degradó después de 6 meses y fue reemplazado por hueso, lo que demuestra la capacidad de estimular la formación de nuevo hueso. Histológicamente, se observó un amplio crecimiento del hueso. En cambio, los defectos vacíos se llenaron sólo con tejido fibroso, confirmando la capacidad osteoconductiva del material. Se llega a la conclusión de que este estudio aporta pruebas de que los implantes de grafito tridimensional fueron capaces de promover el crecimiento de nuevo hueso después de 6 meses de implantación en un modelo de animal grande y que el nuevo modelo de hueso de tubérculo equino coxae que se utilizó es una herramienta prometedora para los estudios de regeneración ósea.Universidad Nacional, Costa RicaEscuela de Medicina Veterinari

Sustained intra-articular release of celecoxib in an equine repeated LPS synovitis model

Synovial inflammation is an important characteristic of arthritic disorders like osteoarthritis and rheumatoid arthritis. Orally administered non-steroidal anti-inflammatory drugs (NSAIDs) such as celecoxib are among the most widely prescribed drugs to manage these debilitating diseases. Intra-articular delivery in biodegradable in situ forming hydrogels overcomes adverse systemic effects and prolongs drug retention in the joint. In this study two formulations of celecoxib (40 mg/g and 120 mg/g) in a propyl-capped PCLA-PEG-PCLA triblock copolymer were sequentially evaluated in a multiple LPS challenge equine synovitis model. Intra-articular release and systemic exposure to celecoxib and local changes at joint level were evaluated longitudinally. A single intra-articular injection of the high dose (HCLB)-gel or low dose (LCLB)-gel showed a sustained and controlled intra-articular release in both inflamed and healthy joints together with very low systemic exposure. Synovitis and lameness were moderate respectively very mild in this model due to the low concentration LPS (0.25 ng/joint). Both celecoxib formulations had a mild, transient effect on inflammatory and structural synovial fluid biomarkers but these returned to baseline within one week of administration. The HCLB-gel showed a significant inhibition in peak white blood cell concentration at 8 hours after LPS induction. Elevated levels of celecoxib were observed in the joint for up to 30 days but no overall anti-inflammatory effects could be observed, which was thought to be due to the moderate synovitis. As there were no long-term adverse effects, sustained intra-articular release of celecoxib from in situ forming hydrogels should be evaluated further for its effects on longer-term relief of inflammatory joint pain in humans and animals

Sustained intra-articular release of celecoxib in an equine repeated LPS synovitis model

Synovial inflammation is an important characteristic of arthritic disorders like osteoarthritis and rheumatoid arthritis. Orally administered non-steroidal anti-inflammatory drugs (NSAIDs) such as celecoxib are among the most widely prescribed drugs to manage these debilitating diseases. Intra-articular delivery in biodegradable in situ forming hydrogels overcomes adverse systemic effects and prolongs drug retention in the joint. In this study two formulations of celecoxib (40 mg/g and 120 mg/g) in a propyl-capped PCLA-PEG-PCLA triblock copolymer were sequentially evaluated in a multiple LPS challenge equine synovitis model. Intra-articular release and systemic exposure to celecoxib and local changes at joint level were evaluated longitudinally. A single intra-articular injection of the high dose (HCLB)-gel or low dose (LCLB)-gel showed a sustained and controlled intra-articular release in both inflamed and healthy joints together with very low systemic exposure. Synovitis and lameness were moderate respectively very mild in this model due to the low concentration LPS (0.25 ng/joint). Both celecoxib formulations had a mild, transient effect on inflammatory and structural synovial fluid biomarkers but these returned to baseline within one week of administration. The HCLB-gel showed a significant inhibition in peak white blood cell concentration at 8 hours after LPS induction. Elevated levels of celecoxib were observed in the joint for up to 30 days but no overall anti-inflammatory effects could be observed, which was thought to be due to the moderate synovitis. As there were no long-term adverse effects, sustained intra-articular release of celecoxib from in situ forming hydrogels should be evaluated further for its effects on longer-term relief of inflammatory joint pain in humans and animals

Sustained Intra-Articular Release and Biocompatibility of Tacrolimus (FK506) Loaded Monospheres Composed of [PDLA-PEG1000]-b-[PLLA] Multi-Block Copolymers in Healthy Horse Joints

There is an increasing interest in controlled release systems for local therapy in the treatment of human and equine joint diseases, aiming for optimal intra-articular concentrations with no systemic side effects. In this study, the intra-articular tolerability and suitability for local and sustained release of tacrolimus (FK506) from monospheres composed of [PDLA-PEG1000 ]-b-PLLA multiblock copolymers were investigated. Unloaded and tacrolimus-loaded (18.4 mg tacrolimus/joint) mono-spheres were injected into the joints of six healthy horses, with saline and hyaluronic acid (HA) in the contralateral joints as controls. Blood and synovial fluid were analysed for the tacrolimus concentration and biomarkers for inflammation and cartilage metabolism. After an initial burst release, sustained intra-articular tacrolimus concentrations (>20 ng/mL) were observed during the 42 days follow-up. Whole-blood tacrolimus levels were below the detectable level (<0.5 ng/mL). A transient inflammatory reaction was observed for all substances, evidenced by increases of the synovial fluid white blood cell count and total protein. Prostaglandin and glycosaminoglycan release were increased in joints injected with unloaded monospheres, which was mitigated by tacrolimus. Both tacrolimus-loaded monospheres and HA transiently increased the concentration of collagen II cleavage products (C2C). A histologic evaluation of the joints at the endpoint showed no pathological changes in any of the conditions. Together, these results indicate the good biocompatibility of intra-articular applied tacrolimus-loaded monospheres combined with prolonged local drug release while minimising the risk of systemic side effects. Further evaluation in a clinical setting is needed to determine if tacrolimus-loaded monospheres can be beneficial in the treatment of inflammatory joint diseases in humans and animals

Sustained Intra-Articular Release and Biocompatibility of Tacrolimus (FK506) Loaded Monospheres Composed of [PDLA-PEG1000]-b-[PLLA] Multi-Block Copolymers in Healthy Horse Joints

There is an increasing interest in controlled release systems for local therapy in the treatment of human and equine joint diseases, aiming for optimal intra-articular concentrations with no systemic side effects. In this study, the intra-articular tolerability and suitability for local and sustained release of tacrolimus (FK506) from monospheres composed of [PDLA-PEG1000]-b-PLLA multiblock copolymers were investigated. Unloaded and tacrolimus-loaded (18.4 mg tacrolimus/joint) monospheres were injected into the joints of six healthy horses, with saline and hyaluronic acid (HA) in the contralateral joints as controls. Blood and synovial fluid were analysed for the tacrolimus concentration and biomarkers for inflammation and cartilage metabolism. After an initial burst release, sustained intra-articular tacrolimus concentrations (&gt;20 ng/mL) were observed during the 42 days follow-up. Whole-blood tacrolimus levels were below the detectable level (&lt;0.5 ng/mL). A transient inflammatory reaction was observed for all substances, evidenced by increases of the synovial fluid white blood cell count and total protein. Prostaglandin and glycosaminoglycan release were increased in joints injected with unloaded monospheres, which was mitigated by tacrolimus. Both tacrolimus-loaded monospheres and HA transiently increased the concentration of collagen II cleavage products (C2C). A histologic evaluation of the joints at the endpoint showed no pathological changes in any of the conditions. Together, these results indicate the good biocompatibility of intra-articular applied tacrolimus-loaded monospheres combined with prolonged local drug release while minimising the risk of systemic side effects. Further evaluation in a clinical setting is needed to determine if tacrolimus-loaded monospheres can be beneficial in the treatment of inflammatory joint diseases in humans and animals

Sustained Intra-Articular Release and Biocompatibility of Tacrolimus (FK506) Loaded Monospheres Composed of [PDLA-PEG1000]-b-[PLLA] Multi-Block Copolymers in Healthy Horse Joints

There is an increasing interest in controlled release systems for local therapy in the treatment of human and equine joint diseases, aiming for optimal intra-articular concentrations with no systemic side effects. In this study, the intra-articular tolerability and suitability for local and sustained release of tacrolimus (FK506) from monospheres composed of [PDLA-PEG1000 ]-b-PLLA multiblock copolymers were investigated. Unloaded and tacrolimus-loaded (18.4 mg tacrolimus/joint) mono-spheres were injected into the joints of six healthy horses, with saline and hyaluronic acid (HA) in the contralateral joints as controls. Blood and synovial fluid were analysed for the tacrolimus concentration and biomarkers for inflammation and cartilage metabolism. After an initial burst release, sustained intra-articular tacrolimus concentrations (>20 ng/mL) were observed during the 42 days follow-up. Whole-blood tacrolimus levels were below the detectable level (<0.5 ng/mL). A transient inflammatory reaction was observed for all substances, evidenced by increases of the synovial fluid white blood cell count and total protein. Prostaglandin and glycosaminoglycan release were increased in joints injected with unloaded monospheres, which was mitigated by tacrolimus. Both tacrolimus-loaded monospheres and HA transiently increased the concentration of collagen II cleavage products (C2C). A histologic evaluation of the joints at the endpoint showed no pathological changes in any of the conditions. Together, these results indicate the good biocompatibility of intra-articular applied tacrolimus-loaded monospheres combined with prolonged local drug release while minimising the risk of systemic side effects. Further evaluation in a clinical setting is needed to determine if tacrolimus-loaded monospheres can be beneficial in the treatment of inflammatory joint diseases in humans and animals